Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1

Interventions

venetoclax 1ruxolitinib 1isatuximab 1daratumumab 1Tissue Plasminogen Activator 1Therapeutics 1Stem Cell Transplantation 1Psychiatric Rehabilitation 1Oxymorphone 1Oxycodone 1Morphine 1Lisaftoclax 1Levorphanol 1Kidney Transplantation 1Hyperthermia, Induced 1Hydromorphone 1Hydrocodone 1Diathermy 1Counseling 1Cell- and Tissue-Based Therapy 1CF regimen 1Abatacept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Hematologic Neoplasms × Lisaftoclax × Clear all
NCT03537482 2024-08-19

APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

Ascentage Pharma Group Inc.

Phase EARLY_PHASE1 Recruiting
90 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡